💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Valproic Acid

CHEMBL109 Phase 4 Zugelassen Small molecule
Half-Life
9-16 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
144.2 g/mol
LogP
2.8
Phase
4

This medication is used to treat epilepsy (multiple seizure types), bipolar disorder (as a mood stabilizer), and to prevent migraines. It works by increasing the levels of the calming neurotransmitter GABA in the brain and by stabilizing electrical activity. It must never be taken during pregnancy due to a high risk of birth defects and developmental problems in the baby, and liver function and blood counts require regular monitoring.

Molekularmasse

144,2110 g/mol

LogP

2,80

TPSA

37,30 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Non-Small Cell Lung Cancer Osteoporosis Asthma Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Melanoma Gastroesophageal Reflux Disease Multiple Sclerosis Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Hypertension Major Depressive Disorder Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Arzneimittelklassen

N — N - Nervous System

Wirkmechanismus

Enhances GABA transmission and blocks sodium/calcium channels.

Pharmacokinetics (PK)

Half-Life 9-16 hours

Pharmacodynamics (PD)

Mechanismus

Enhances GABA transmission and blocks sodium/calcium channels.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCC(CCC)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

                

                

                

                    
                    

                        
Molecular Formula

                        
C8H16O2

                    

                    
                    

                        
HBD / HBA

                        
1 / 2

                    

                    
                    

                        
Rotierbare Bindungen

                        
5

                    

                    
                    
                    

                        
Schwere Atome

                        
10

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            SCN9A (Sodium Channel Nav1.7)
                            Blocker
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            GABRA1 (GABA-A Receptor)
                            Agonist
                        

                        
                    

                    
                    

                        

                            CYP2D6 (Cytochrome P450 2D6)
                            Inhibitor
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Valproic Acid + Warfarin
                            
                        

                        
                        
Valproic acid can displace warfarin from plasma protein binding sites and may inhibit platelet aggregation, increasing bleeding risk.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Valproic Acid + Topiramate
                            
                        

                        
                        
The combination of topiramate and valproic acid is associated with hyperammonemia and encephalopathy even without hepatotoxicity, representing a unique metabolic interaction.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Valproic Acid + Lamotrigine
                            
                        

                        
                        
Valproic acid doubles lamotrigine plasma concentrations by inhibiting its glucuronidation; the combination is associated with Stevens-Johnson syndrome and toxic epidermal necrolysis.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Valproic Acid + Gabapentin
                            
                        

                        
                        
Gabapentin and valproic acid have a minor pharmacokinetic interaction; valproate may slightly increase gabapentin renal clearance.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Valproic Acid + Phenytoin
                            
                        

                        
                        
Valproic acid displaces phenytoin from protein binding and inhibits its metabolism, leading to increased free phenytoin levels despite total levels that may appear unchanged or decreased.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Valproic Acid + Carbamazepine
                            
                        

                        
                        
Carbamazepine reduces valproic acid levels through enzyme induction, while valproic acid inhibits epoxide hydrolase, increasing the toxic carbamazepine-10,11-epoxide metabolite.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
This medication is used to treat epilepsy (multiple seizure types), bipolar disorder (as a mood stabilizer), and to prevent migraines. It works by increasing the levels of the calming neurotransmitter GABA in the brain and by stabilizing electrical activity. It must never be taken during pregnancy due to a high risk of birth defects and developmental problems in the baby, and liver function and blood counts require regular monitoring.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Enhances GABA transmission and blocks sodium/calcium channels.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Valproic Acid: Half-life: 9-16 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Valproic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL109.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3121.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.